Three Gut Peptides, Ranked by Evidence Instead of Hype

Search for peptides and gut health and you will find the same three names: BPC-157, KPV, and larazotide. They get discussed as if they were interchangeable options on a menu.

They are not. The gap between them in human evidence is enormous, and it runs in an awkward direction. Ranked by how much has actually been shown in people, the order is close to the opposite of how easy each one is to obtain.

1. Larazotide: real trials, including one that failed

Larazotide is the only one of the three with Phase 3 human trial data in a condition driven by gut permeability.

It is an eight amino acid peptide designed to tighten the junctions between the cells lining your intestine, working against a protein called zonulin that loosens them. In Phase 2 trials, people with celiac disease taking larazotide alongside a gluten challenge had less severe symptoms than those on placebo. A meta-analysis of the randomized trials found it safe and better than placebo for symptom relief.

Then the Phase 3 trial missed its primary endpoint in 2022.

That failure is the most useful piece of information in this entire article. Larazotide had a plausible mechanism, encouraging mid stage results, real funding, and proper trial design, and it still did not clear the final bar. If a compound with all of that can fail, compounds with none of it deserve considerably more skepticism than they usually get.

Larazotide is not approved and not commercially available.

2. BPC-157: enormous animal literature, almost no humans

BPC-157 has by far the most research behind it by volume, and by far the most enthusiastic user base. In animals it repairs gut lining damage consistently across many studies, and it is one of the few peptides people take orally for gut problems specifically.

The problem is the species. As of early 2026, published human studies of BPC-157 amounted to about three small pilots totaling fewer than thirty people, and none were in inflammatory bowel disease or IBS. We went through that evidence base in detail in our piece on what the human research actually shows.

Hundreds of animal papers do not substitute for one adequate human trial. They justify running the trial. That trial has not been run for gut conditions.

3. KPV: the most elegant mechanism, the least human data

KPV is a tripeptide clipped from the end of alpha-MSH, one of your body's natural anti-inflammatory hormones. On paper it is the most satisfying of the three.

Unlike most peptides, it survives being swallowed. Intestinal cells actively pull it in through a transporter called PepT1, so an oral dose reaches inflamed gut tissue directly. Once inside, it interferes with NF-kB, a master switch for inflammatory genes. The anchor study, a 2008 paper in Gastroenterology, showed oral KPV reduced inflammation in two separate mouse models of colitis.

That is a clean story, and it is entirely a mouse story. No completed randomized human trial has tested KPV on its own for any condition. Every dosing protocol in circulation is extrapolated or copied between clinics rather than derived from evidence.

The inversion

Put the three together and the pattern is uncomfortable.

• Larazotide has the best human evidence and you cannot buy it.
• BPC-157 has the largest animal literature, almost no human data, and is sold everywhere.
• KPV has the most appealing mechanism, no human trials at all, and is widely available.

Availability is not tracking evidence here. If anything it is tracking the reverse, because the compounds that went through proper development are the ones that can fail publicly and get pulled, while the ones sold as research chemicals never face that test.

The July FDA advisory vote, which recommended BPC-157 and KPV for compounding, may change where people buy these. It does not change any of the above.

About leaky gut

A word on the phrase, since it drives most of this traffic.

Intestinal permeability is a real, measurable thing. Tight junctions between intestinal cells can loosen, and that can be quantified in a laboratory. That part is not controversial.

What remains contested is how much of it causes the symptoms people attribute to it, and whether tightening those junctions makes people feel better. Larazotide was the most serious attempt anyone has made to answer that second question, and its Phase 3 result was not encouraging. That does not close the question, but it should temper confident claims in either direction.

What to do instead

None of these three is approved for any gut condition, and none is a substitute for finding out what is actually wrong. Persistent digestive symptoms are worth investigating properly, because celiac disease, inflammatory bowel disease, and infections all have real treatments with real evidence.

The interventions with the strongest data for gut symptoms remain unglamorous ones: identifying trigger foods, treating the underlying condition, and in some cases specific dietary approaches supervised by a dietitian. None of that sells peptides, which is roughly why you read less about it.

Our gut health section covers each of these three in full, including dosing protocols where they exist and honest notes where they do not.

Sources: American Journal of Physiology: larazotide acetate and tight junction regulation and systematic review and meta-analysis of larazotide trials in celiac disease.